Bychkov, Dmitrii
Linder, Nina
Tiulpin, Aleksei
Kücükel, Hakan
Lundin, Mikael
Nordling, Stig
Sihto, Harri
Isola, Jorma
Lehtimäki, Tiina
Kellokumpu-Lehtinen, Pirkko-Liisa
von Smitten, Karl
Joensuu, Heikki
Lundin, Johan
Funding for this research was provided by:
Biomedicum Helsinki Foundation
Orion-Pharmos Research Foundation
iCAN Digital Precision Cancer Medicine Program
Sigrid Jusélius Foundation
Finska Läkaresällskapet
HiLIFE Helsinki Institute of Life Sciences
Article History
Received: 3 September 2020
Accepted: 29 January 2021
First Online: 17 February 2021
Competing interests
: Johan Lundin and Mikael Lundin are the founders and co-owners of Aiforia Technologies Oy, Helsinki, Finland. Heikki Joensuu is employed by Orion Pharma, serves as the Chairman of the Advisory Board of Neutron Therapeutics, has received funds from Neutron Therapeutics and owns stocks of Orion Pharma and Sartar Therapeutics. Aleksei Tiulpin is a co-founder, shareholder, and CTO of Ailean Technologies Oy. The other authors have no conflicts of interest.